(Reuters) -Eli Lilly has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs targeting cardiometabolic diseases and obesity, Superluminal said on Thursday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Comments